AsiDNA

DRUG4 trials

Sponsors

Valerio Therapeutics, Gustave Roussy, Cancer Campus, Grand Paris, Institut Curie

Conditions

Advanced CancerBreast CancerMetastatic Castration-resistant Prostate CancerOvarian CancerRecurrent Epithelial Ovarian CancerRecurrent High-grade Glioma

Phase 1

AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors

CompletedNCT03579628

Valerio TherapeuticsAdvanced Cancer

Start: 2018-04-05End: 2022-02-20Updated: 2022-03-24

Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

TerminatedNCT04826198

Gustave Roussy, Cancer Campus, Grand ParisOvarian Cancer

Start: 2020-10-05End: 2024-04-04Updated: 2024-12-05

AsiDNA Children, Adolescents and Young Adults

TerminatedNCT05394558

Institut CurieRecurrent High-grade Glioma

Start: 2022-05-27End: 2023-09-20Updated: 2023-12-26

Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

CompletedNCT05700669

Valerio TherapeuticsBreast Cancer, Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer

Start: 2023-02-20End: 2023-10-31Updated: 2024-09-19

Related Papers

Abstract 2600: AsiDNA® treatment protects healthy cells from anticancer treatment toxicity

Cancer Research2022-06-15

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours.

2020-08-255 citations